The introduction of the Commercial Insurance Innovative Drug List marks a significant step in the coordinated development of public and private health insurance, creating a market-driven payment channel that enhances access to innovative therapies.
"When chemotherapy is the only option, what we need is not just technology but also the courage to pay," wrote a nasopharyngeal cancer patient in a personal account. This sentiment reflects the plight of countless patients facing exorbitant costs for life-saving innovative drugs—hope often crushed by financial barriers, especially in rare disease treatments where annual expenses can reach hundreds of thousands of yuan.
A new solution is emerging. On December 13, the National Healthcare Security Administration (NHSA) announced plans to support commercial health insurance in 2026, emphasizing the rollout of the Commercial Insurance Innovative Drug List. This initiative will enable "one-stop" settlement services combining public and private insurance, pending patient authorization and data security safeguards.
On December 7, the 2025 National Reimbursement Drug List (NRDL) and the inaugural Commercial Insurance Innovative Drug List were released in Guangzhou, effective January 1, 2026. The NHSA’s first-ever commercial insurance list includes 19 drugs, covering CAR-T therapies, rare disease treatments like neuroblastoma, and high-profile Alzheimer’s drugs.
The NHSA stated that the list prioritizes high-innovation, high-value drugs beyond basic医保 coverage, serving as a reference for commercial insurers and mutual aid programs. This complements the NRDL, clarifying boundaries for public insurance while fostering private-sector growth.
Notably, five CAR-T therapies—priced around ¥1 million per dose—were included after years of failing NRDL negotiations due to cost concerns. Experts argue that while innovation deserves support, fairness demands multi-tiered payment solutions for premium-priced drugs.
A Shanghai clinician noted the list empowers patients with more choices, enabling families to access cutting-edge treatments through products like "Huimin Insurance."
The list may act as a "transition pool" for the NRDL, allowing drugs to accumulate real-world data before potential public coverage. However, this mechanism remains undefined.
The emerging model—"basic医保 for普惠, commercial lists for innovation"—could resolve bottlenecks where expensive drugs struggle with hospital adoption. A梯度准入闭环 ("commercial first, public later") is envisioned for drugs暂未covered by public insurance.
Challenges persist: balancing drug pricing, insurer costs, and patient access; strengthening data integration and actuarial models; and improving医疗-payment coordination. Hospitals’ drug evaluation committees remain a key barrier post-listing.
Insurers like镁信健康 view this as a milestone in China’s multi-tiered healthcare, enabling commercial insurance to evolve into strategic purchasers of innovative therapies. Per the "Healthy China 2030" blueprint, the sector could grow to ¥16 trillion by 2030, with tailored insurance products and health management services as new frontiers.
Among the 19 listed drugs, CAR-Ts dominated discussions. Products like Fosun Kite’s阿基仑赛 and JW Therapeutics’瑞基奥仑赛 were included after price negotiations reportedly yielded steeper discounts than expected. Patients may save tens of thousands annually, though落地细节remain unclear.
The list also addresses rare diseases and Alzheimer’s, with Eli Lilly’s donanemab and Eisai’s lecanemab (priced at ¥2,508–¥5,500 per vial) included to ease chronic disease burdens.
Price negotiation mechanics mirror NRDL processes but involve insurer rebates rather than public price cuts. For instance, a 20% manufacturer rebate could boost patient reimbursement rates or expand drug coverage in plans like Huimin Insurance.
Group insurance is seen as critical for market expansion. Shanghai is piloting "new group insurance" models inspired by France’s layered coverage, where团体险covers 85% of U.S. innovative drug payments.
Post-launch, the NHSA may require insurers to complete initial settlements within three months for evaluation. While the list exempts drugs from DRG/DIP and procurement替代metrics, hospital adoption hurdles persist.
Experts propose standardizing products with government oversight—akin to Huimin Insurance’s success—and渐进式reforms where commercial insurance tests drugs before public coverage. This "transition pool" concept could reshape China’s pharma innovation ecosystem, offering manufacturers market entry and real-world data for future NRDL bids.
For insurers, it expands product differentiation; for patients, faster access. As对外经济贸易大学’s孙洁 noted, listing boosts hospital entry chances and involves milder price cuts than NRDL negotiations—a win for volume-driven pharma firms like BeiGene and Innovent.
Analysts predict the list will elevate clinical standards and R&D returns, particularly for pipeline-rich innovators. However, sustainability hinges on insurers’ risk management and public-private衔接mechanisms, per Fudan University’s陈冬梅.
The policy exempts listed drugs from hospital cost-control metrics, but provincial authorities may monitor retail pharmacy pricing. Real-world evaluations are encouraged to assess value.
Ultimately, this shift from单一保障to多层次协同reflects China’s healthcare modernization—a system learning to balance innovation, affordability, and sustainability.